Venus Remedies Expands Oncology Wing with Marketing Approvals from Four Key Markets
Mumbai, July 05, 2023: Venus Remedies Ltd, global provider of affordable cancer drugs, has achieved significant milestones in its expansion plans in the oncology space. The company has obtained marketing approvals for key chemotherapy drugs from Oman, Malaysia, Bosnia, and Trinidad & Tobago, solidifying its position in the Gulf Cooperation Council (GCC), Association of Southeast Asian Nations (ASEAN), Balkan, and Caribbean regions. With these regulatory successes, Venus Remedies now boasts a remarkable total of 503 marketing approvals for its oncology products across 75 countries.
Company to extend its operations to new territories and provide advanced cancer treatment options
This strategic move reflects Venus Remedies’ commitment to becoming a leading supplier of oncology medicines from India in the ASEAN region. The company has recently received product registration for pemetrexed, a widely used chemotherapy drug, in Malaysia, which serves as a significant market in the ASEAN region. Additionally, Venus Remedies anticipates the marketing authorization for docetaxel, another commonly prescribed cancer drug, from Oman. This achievement is expected to expand the company’s reach in the GCC region, where it offers an extensive range of oncology products.
Saransh Chaudhary, President of Global Critical Care at Venus Remedies, expressed enthusiasm about the marketing approvals, stating that they would enable the company to extend its operations to new territories and provide advanced cancer treatment options with improved outcomes for patients. Chaudhary emphasized Venus Remedies’ dedication to addressing unmet medical needs in oncology and critical care segments.
Provider of Cancer Drugs Secures Regulatory Milestones in GCC, ASEAN, Balkan, and Caribbean Regions
The market potential in Malaysia is particularly promising for Venus Remedies, with its $2.8-billion pharmaceutical market. The company has already secured marketing approval for 27 products across various segments in Malaysia, and the product registration for pemetrexed is expected to pave the way for faster approval of the drug in other ASEAN countries. Furthermore, Venus Remedies has submitted dossiers for nine additional marketing authorizations in Malaysia, including two oncology products.
Venus Remedies’ expansion efforts extend beyond the ASEAN region. The marketing approval for docetaxel in Oman, a pharmaceutical market valued at $1.4 billion, is anticipated to facilitate the registration process in other Gulf countries with similar regulatory requirements. Similarly, the company’s first marketing authorization in Bosnia for gemcitabine, in the Euro 334-million pharma market, is expected to streamline the registration process in the entire Balkan region. Additionally, Venus Remedies has obtained marketing approvals for three oncology products in Trinidad & Tobago, further strengthening its commitment to providing affordable generic alternatives to cancer patients.
